{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:45:26Z","timestamp":1794260726505,"version":"4.9.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T00:00:00Z","timestamp":1669680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Niraparib was approved for the treatment of platinum-sensitive recurrent epithelial ovarian cancer, fallopian tube and primary peritoneal cancer. The authors retrospectively investigated niraparib-related adverse events (AEs) through data mining of the US Food and Drug Administration Adverse Event Reporting System (FAERS). Four algorithms were employed to quantify the signals of niraparib associated AEs, using data from the FAERS between 2017 and 2021. MYSQL 8.0, Navicat Premium 15, Microsoft EXCEL 2019 and the GraphPad Prism 8 were used to conduct statistical analysis. There are 7,238,157 reports collected from the FAERS database, of which 11,701 reports listed niraparib as the \u2018primary suspected (PS)\u2019 drug. A total of 97 significant disproportionality PTs conforming to the four algorithms were simultaneously retained. Unexpected significant AEs such as neuropathy peripheral, photosensitivity reaction, gastrooesophageal reflux disease might also occur. The median onset time of niraparib-associated AEs was 18\u00a0days (interquartile range [IQR] 4\u201366\u00a0days), and most of the cases occurred within the first months after niraparib initiation. The study found niraparib-associated AEs and might provide important support for clinical monitoring and risk identification of niraparib.<\/jats:p>","DOI":"10.1038\/s41598-022-23726-4","type":"journal-article","created":{"date-parts":[[2022,11,29]],"date-time":"2022-11-29T21:51:54Z","timestamp":1669758714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib"],"prefix":"10.1038","volume":"12","author":[{"given":"Menglin","family":"Guo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamin","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guosong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,29]]},"reference":[{"key":"23726_CR1","doi-asserted-by":"publisher","first-page":"7170","DOI":"10.1021\/jm901188v","volume":"52","author":"P Jones","year":"2009","unstructured":"Jones, P. et al. Discovery of 2-{4-[(3S)-piperidin-3-yl] phenyl}-2H-indazole-7-carboxamide(MK-4827): A novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors. J. Med. Chem. 52, 7170\u20137185 (2009).","journal-title":"J. Med. Chem."},{"key":"23726_CR2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux, S., Braunstein, M. & Oza, A. M. Epithelial ovarian cancer: Evolution of management in the era of precision medicine. CA Cancer J. Clin. 69, 280\u2013304 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"23726_CR3","unstructured":"Niraparib (ZEJULA)[EB\/OL]. https: \/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/208447s012lbl. pdf. (2020-02-27) [2020-04-18]."},{"key":"23726_CR4","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza, M. R. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154\u20132164 (2016).","journal-title":"N. Engl. J. Med."},{"key":"23726_CR5","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s11864-022-00938-4","volume":"23","author":"M Smith","year":"2022","unstructured":"Smith, M. & Pothuri, B. Appropriate selection of PARP inhibitors in ovarian cancer. Curr. Treat. Options Oncol. 23, 887\u2013903 (2022).","journal-title":"Curr. Treat. Options Oncol."},{"key":"23726_CR6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonz\u00e1lez-Mart\u00edn","year":"2019","unstructured":"Gonz\u00e1lez-Mart\u00edn, A. et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N. Engl. J. Med. 381, 2391\u20132402 (2019).","journal-title":"N. Engl. J. Med."},{"key":"23726_CR7","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S1470-2045(19)30515-7","volume":"20","author":"MR Mirza","year":"2019","unstructured":"Mirza, M. R. et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVA\u2013NOVA2\/ENGOT-ov24): A randomised, phase 2, superiority trial. Lancet Oncol. 20, 1409\u20131419 (2019).","journal-title":"Lancet Oncol."},{"key":"23726_CR8","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1470-2045(19)30029-4","volume":"20","author":"KN Moore","year":"2019","unstructured":"Moore, K. N. et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): A multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol. 20, 636\u2013648 (2019).","journal-title":"Lancet Oncol."},{"key":"23726_CR9","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.annonc.2020.12.018","volume":"32","author":"XH Wu","year":"2021","unstructured":"Wu, X. H. et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): A randomized, double-blind, placebo-controlled phase III trial. Ann. Oncol. 32, 512\u2013521 (2021).","journal-title":"Ann. Oncol."},{"key":"23726_CR10","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ygyno.2020.09.006","volume":"159","author":"MR Mirza","year":"2020","unstructured":"Mirza, M. R. et al. Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16\/NOVA trial. Gynecol. Oncol. 159, 442\u2013448 (2020).","journal-title":"Gynecol. Oncol."},{"key":"23726_CR11","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s11523-021-00841-2","volume":"16","author":"A Lee","year":"2021","unstructured":"Lee, A. Niraparib: A review in first-line maintenance therapy in advanced ovarian cancer. Target Oncol. 16, 839\u2013845 (2021).","journal-title":"Target Oncol."},{"key":"23726_CR12","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40264-021-01082-y","volume":"44","author":"J Setyawan","year":"2021","unstructured":"Setyawan, J., Azimi, N., Strand, V., Yarur, A. & Fridman, M. Reporting of thromboembolic events with JAK inhibitors: Analysis of the FAERS database 2010\u20132019. Drug Saf. 44, 889\u2013897 (2021).","journal-title":"Drug Saf."},{"key":"23726_CR13","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40264-019-00899-y","volume":"43","author":"U Vogel","year":"2020","unstructured":"Vogel, U. et al. Investigating overlap in signals from EVDAS, FAERS, and VigiBase. Drug Saf. 43, 351\u2013362 (2020).","journal-title":"Drug Saf."},{"key":"23726_CR14","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1101\/gad.334516.119","volume":"34","author":"D Slade","year":"2020","unstructured":"Slade, D. PARP and PARG inhibitors in cancer treatment. Genes Dev. 34, 360\u2013394 (2020).","journal-title":"Genes Dev."},{"key":"23726_CR15","doi-asserted-by":"publisher","first-page":"4405","DOI":"10.3390\/cancers13174405","volume":"13","author":"V Bezrookove","year":"2021","unstructured":"Bezrookove, V. et al. Niraparib suppresses cholangiocarcinoma tumor growth by inducing oxidative and replication stress. Cancers (Basel) 13, 4405 (2021).","journal-title":"Cancers (Basel)"},{"key":"23726_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00280-021-04249-7","volume":"88","author":"F Saad","year":"2021","unstructured":"Saad, F. et al. Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: Safety and pharmacokinetic results from a phase 1b study (BEDIVERE). Cancer Chemother. Pharmacol. 88, 25\u201337 (2021).","journal-title":"Cancer Chemother. Pharmacol."},{"key":"23726_CR17","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/S1470-2045(21)00757-9","volume":"23","author":"MR Smith","year":"2022","unstructured":"Smith, M. R. et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): A multicentre, open-label, phase 2 trial. Lancet Oncol. 23, 362\u2013373 (2022).","journal-title":"Lancet Oncol."},{"key":"23726_CR18","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","volume":"5","author":"S Vinayak","year":"2019","unstructured":"Vinayak, S. et al. Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer. JAMA Oncol. 5, 1132\u20131140 (2019).","journal-title":"JAMA Oncol."},{"key":"23726_CR19","doi-asserted-by":"publisher","first-page":"5482","DOI":"10.1158\/1078-0432.CCR-21-0310","volume":"27","author":"NC Turner","year":"2021","unstructured":"Turner, N. C. et al. Niraparib for Advanced Breast Cancer with Germline BRCA1 and BRCA2 Mutations: The EORTC 1307-BCG\/BIG5-13\/TESARO PR-30-50-10-C BRAVO Study. Clin. Cancer Res. 27, 5482\u20135491 (2021).","journal-title":"Clin. Cancer Res."},{"key":"23726_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1002\/cncr.33885","volume":"128","author":"SS Ramalingam","year":"2022","unstructured":"Ramalingam, S. S. et al. JASPER: Phase 2 trial of first-line niraparib plus pembrolizumab in patients with advanced non-small cell lung cancer. Cancer 128, 65\u201374 (2022).","journal-title":"Cancer"},{"key":"23726_CR21","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1001\/jamaoncol.2015.5941","volume":"2","author":"SM Rosenberg","year":"2016","unstructured":"Rosenberg, S. M. et al. BRCA1 and BRCA2 mutation testing in young women with breast cancer. JAMA Oncol. 2, 730\u2013736 (2016).","journal-title":"JAMA Oncol."},{"key":"23726_CR22","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.3390\/cancers14092230","volume":"14","author":"J Huang","year":"2022","unstructured":"Huang, J. et al. Worldwide burden, risk factors, and temporal trends of ovarian cancer: A global study. Cancers (Basel) 14, 2230 (2022).","journal-title":"Cancers (Basel)"},{"key":"23726_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1080\/14740338.2022.2016696","volume":"21","author":"Y Shu","year":"2022","unstructured":"Shu, Y., Ding, Y., Dai, B. & Zhang, Q. A real-world pharmacovigilance study of axitinib: Data mining of the public version of FDA adverse event reporting system. Expert Opin. Drug Saf. 21, 563\u2013572 (2022).","journal-title":"Expert Opin. Drug Saf."},{"key":"23726_CR24","doi-asserted-by":"publisher","first-page":"2968","DOI":"10.1200\/JCO.18.02238","volume":"37","author":"JMD Campo","year":"2019","unstructured":"Campo, J. M. D. et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA Trial. J. Clin. Oncol. 37, 2968\u20132973 (2019).","journal-title":"J. Clin. Oncol."},{"key":"23726_CR25","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s12012-018-9462-2","volume":"18","author":"RJ Henning","year":"2018","unstructured":"Henning, R. J., Bourgeois, M. & Harbison, R. D. Poly(ADP-ribose) polymerase (PARP) and PARP inhibitors: Mechanisms of action and role in cardiovascular disorders. Cardiovasc. Toxicol. 18, 493\u2013506 (2018).","journal-title":"Cardiovasc. Toxicol."},{"key":"23726_CR26","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.molcel.2015.07.019","volume":"59","author":"H Zhao","year":"2015","unstructured":"Zhao, H. et al. PARP1\u2014and CTCF-mediated interactions between active and repressed chromatin at the lamina promote oscillating transcription. Mol. Cell 59, 984\u2013997 (2015).","journal-title":"Mol. Cell"},{"key":"23726_CR27","doi-asserted-by":"publisher","first-page":"e89","DOI":"10.1017\/S2045796019000829","volume":"29","author":"L Grassi","year":"2020","unstructured":"Grassi, L. Psychiatric and psychosocial implications in cancer care: The agenda of psycho-oncology. Epidemiol. Psychiatr. Sci. 29, e89 (2020).","journal-title":"Epidemiol. Psychiatr. Sci."},{"key":"23726_CR28","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1089\/jpm.2018.0572","volume":"22","author":"R Balko","year":"2019","unstructured":"Balko, R., Hurley, R. & Jatoi, A. Poly (ADP-Ribose) polymerase inhibition for chemotherapy-induced peripheral neuropathy: A meta-analysis of placebo-controlled trials. J. Palliat. Med. 22, 977\u2013980 (2019).","journal-title":"J. Palliat. Med."},{"key":"23726_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1634\/theoncologist.2019-0565","volume":"25","author":"J Zhang","year":"2020","unstructured":"Zhang, J. et al. Phase I pharmacokinetic study of niraparib in Chinese patients with epithelial ovarian cancer. Oncologist 25, 19-e10 (2020).","journal-title":"Oncologist"},{"key":"23726_CR30","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1200\/JCO.19.00917","volume":"37","author":"UA Matulonis","year":"2019","unstructured":"Matulonis, U. A. et al. Niraparib maintenance treatment improves time without symptoms or toxicity (TWiST) versus routine surveillance in recurrent ovarian cancer: A TWiST analysis of the ENGOT-OV16\/NOVA trial. J. Clin. Oncol. 37, 3183\u20133191 (2019).","journal-title":"J. Clin. Oncol."},{"key":"23726_CR31","unstructured":"FDA FAERS public dashboard. Available at https:\/\/fifis.fda.gov\/extensions\/fpdwidgets\/2e01da82-13fe-40e0-8c38-4da505737e36.html. Accessed April 12, 2021."},{"key":"23726_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5062","author":"Y Shu","year":"2022","unstructured":"Shu, Y. et al. Hematological toxicities in PARP inhibitors: A real-world study using FDA adverse event reporting system (FAERS) database. Cancer Med. https:\/\/doi.org\/10.1002\/cam4.5062 (2022).","journal-title":"Cancer Med."},{"key":"23726_CR33","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","volume":"19","author":"L Peng","year":"2020","unstructured":"Peng, L., Xiao, K., Ottaviani, S., Stebbing, J. & Wang, Y. A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for baricitinib. Expert Opin. Drug Saf. 19, 1505\u20131511 (2020).","journal-title":"Expert Opin. Drug Saf."},{"key":"23726_CR34","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2165\/00002018-200023060-00004","volume":"23","author":"M Lindquist","year":"2000","unstructured":"Lindquist, M., St\u00e5hl, M., Bate, A., Edwards, I. R. & Meyboom, R. H. A retrospective evaluation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf. 23, 533\u2013542 (2000).","journal-title":"Drug Saf."},{"key":"23726_CR35","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/pds.5265","volume":"30","author":"M Hauben","year":"2021","unstructured":"Hauben, M., Zou, C., Bright, S. & Hung, E. More extreme duplication in the U.S. FDA FAERS databaseand a suggested check point for disproportionality analysis. Pharmacoepidemiol. Drug Saf. 30, 1140\u20131141 (2021).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"23726_CR36","doi-asserted-by":"publisher","first-page":"106601","DOI":"10.1016\/j.intimp.2020.106601","volume":"84","author":"Y Hu","year":"2020","unstructured":"Hu, Y. et al. Colitis following the use of immune checkpoint inhibitors: A real-worldanalysis of spontaneous reports submitted to the FDA adverse event reporting system. Int. Immunopharmacol. 84, 106601 (2020).","journal-title":"Int. Immunopharmacol."},{"key":"23726_CR37","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda, T., Tamon, A., Kadoyama, K. & Okuno, Y. Data mining of the public version of the FDA adverse event reporting system. Int. J. Med. Sci. 10, 796\u2013803 (2013).","journal-title":"Int. J. Med. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23726-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23726-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23726-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T05:11:37Z","timestamp":1701493897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-23726-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,29]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["23726"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-23726-4","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,29]]},"assertion":[{"value":"7 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20601"}}